Engineered Exosome Platform
Built on Echo Biotech's peer-reviewed PLXNA1 scaffold technology, the Echosome® engineered extracellular vesicle platform supports active EV sorting and configurable cargo placement, enabling surface display, luminal loading and coordinated dual-side designs for selected protein and RNA strategies.
Quick Facts
- PLXNA1 EV Sorting: High EV-sorting scaffold technology for configurable protein and RNA-oriented engineering strategies.
- Surface Display: Supports targeting ligands, antibodies, nanobodies, peptides and selected functional proteins on the EV surface.
- Luminal Loading: Supports protected intravesicular cargo placement for selected proteins, fusion proteins and RNA-binding module strategies.
- Dual-Cargo Design: Combines surface targeting or functional display with selected luminal cargo designs.
- Analytical Characterization: Confirms identity, loading, orientation, purity, potency, stability and batch consistency.
- Translational Development: Connects feasibility assessment, lead optimization, process development and GMP-oriented preparation.
PLXNA1: A Novel High EV-Sorting Scaffold
Echo Biotech identified PLXNA1 through systematic screening and multi-method validation. A truncated PLXNA1 architecture retains strong EV-sorting capability while creating configurable fusion sites for extracellular and intravesicular engineering.
Why PLXNA1?: Unlike many conventional scaffold proteins, PLXNA1 can support fusion engineering at both ends of the scaffold, providing a flexible framework for distinct cargo orientations and development objectives.
Strong EV sorting demonstrated by mass spectrometry, Western blot, ELISA and nano-flow cytometry.
Flexible orientation supporting N-terminal surface display and C-terminal luminal loading.
Broad cargo design space evaluated with proteins, peptides and RNA-binding modules.
Functional retention for selected cargoes after EV loading.
Development flexibility for single-cargo and coordinated dual-cargo engineering strategies.
Start with biology: define the desired interaction, cellular target and pharmacology.
Place cargo deliberately: choose surface or luminal orientation based on the intended function.
Engineer for manufacturability: evaluate expression, EV sorting, product quality and scalable production together.
Build an analytical package: confirm identity, loading, orientation, potency, purity, stability and batch consistency.
PLXNA1-Based Dual-Side Engineering
Configure cargo location and orientation to match the intended biology, mechanism and target product profile.
N-Terminal / Extracellular Surface Display: Targeting ligands for cell- or tissue-directed programs; Antibodies and nanobodies for molecular recognition; Cytokines, enzymes and other functional proteins; Peptides and compact functional motifs
C-Terminal / Intravesicular Luminal Loading: Therapeutic or reporter proteins protected within the EV lumen; Fusion proteins combining functional and loading modules; RNA-binding modules for selected RNA cargo strategies; Coordinated dual-cargo designs with surface targeting
Proteins: Cytokines, growth factors, enzymes, reporters and other functional proteins.
Targeting Molecules: Antibodies, nanobodies, receptor-binding domains and selected targeting ligands.
Peptides: Compact targeting, penetration or functional peptide motifs.
RNA Strategies: Selected mRNA or other RNA approaches supported through engineered binding modules.
Coordinated dual-cargo engineering can combine a surface-displayed targeting or functional molecule with a selected luminal cargo. Cargo ratio, construct design and producer-cell expression can be optimized as an integrated system.
Published Evidence and Development Performance
Selected results demonstrate the scientific foundation of PLXNA1 engineering. Published study findings and internal platform development data are clearly distinguished below.
PLXNA1 EV Enrichment: 489.6x
Versus PTGFRN: >5x
Model mRNA Loading: >10x
Target-Protein-Positive EVs: >80%
The first three metrics are study-specific experimental findings reported by Zhao et al. (2024). The >80% target-protein-positive EV result reflects selected Echo Biotech platform development data; performance may vary with cargo, construct, producer cell, process and analytical method. These results are not clinical outcomes.
Integrated Engineering Workflow
A stage-gated path from molecular concept to a characterized, scalable engineered EV candidate.
Design: Define cargo, orientation, mechanism and target product profile.
Build: Construct PLXNA1 fusion architectures and establish selected producer-cell systems.
Produce: Generate engineered EVs under controlled, scalable culture conditions.
Purify: Develop recovery and purification conditions suited to the intended scale and quality target.
Characterize: Confirm identity, loading, orientation, purity, potency, stability and consistency.
Translate: Advance selected candidates into preclinical and GMP-oriented process development.
Build the Right EV Architecture for Your Cargo
Echo Biotech combines molecular engineering with EV preparation, purification, characterization and scale-up capabilities to support feasibility studies and translational development.
Molecular & Construct Design: Cargo orientation, linker design, expression architecture, fusion topology and coordinated dual-cargo strategy.
Producer-Cell Engineering: Transient screening, stable-cell development, monoclonal selection and expression optimization.
EV Production: Controlled cell culture, scalable production strategy and process parameter development.
Purification Development: Recovery, concentration, buffer exchange and multi-step purification tailored to the product profile.
Analytical Characterization: Particle attributes, identity, cargo loading, orientation, purity, morphology and product consistency.
Potency & Stability: Cargo-specific binding, enzymatic, signaling or cell-based functional assays plus formulation and stability studies.
Expandable Across Multiple Biological Strategies
The platform can be adapted to research and development programs that require controlled cargo placement, functional surface display or protected luminal delivery.
Immunomodulation: Cytokines, immune checkpoints and regulatory factors for controlled immune-signaling research.
Tissue Repair & Regeneration: Growth factors and signaling proteins for tissue-repair and regenerative research programs.
Targeted Delivery: Ligand- or antibody-directed EV architectures for selected cell and tissue targets.
Neurological Research: Neurotrophic factors and selected RNA strategies for central or peripheral nervous-system research.
Metabolic & Inflammatory Disease: Engineered proteins and RNA approaches designed around defined disease mechanisms.
Oncology Research: Tumor antigens, immune activators, targeting ligands and selected RNA cargoes for preclinical evaluation.
From Feasibility to Translational Development
Programs can start with a focused scaffold and cargo feasibility assessment, then expand into lead optimization, stable-cell development, process development, analytical characterization and preclinical material supply.
Feasibility assessment and architecture selection
Construct screening and cargo-orientation optimization
Lead candidate and producer-cell development
Process, analytical and formulation development
Preclinical and GMP-oriented development support
Share your cargo type, desired orientation, target biology and development stage. Our team can assess scaffold compatibility and propose a practical engineered EV development route.
Reference
Zhao H, Li Z, Liu D, et al. PlexinA1 (PLXNA1) as a novel scaffold protein for the engineering of extracellular vesicles. Journal of Extracellular Vesicles. 2024;13:e70012. doi:10.1002/jev2.70012.